Sugi Predict

Sugi Predict / Targets / CDK11B

CDK11B

Cyclin-dependent kinase 11B · P21127 · CDK11B on Sugi Atlas →

4,531 patent compounds predicted against CDK11B, 3,731 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Bms-345541 Bms-345541 (SCHEMBL118886) 1.00 2/20
SCHEMBL1279465 SCHEMBL1279465 0.86 2/20
SCHEMBL3522935 SCHEMBL3522935 0.59 2/20
SCHEMBL1168934 SCHEMBL1168934 0.53 2/20
SCHEMBL2814584 SCHEMBL2814584 0.52 2/20
SCHEMBL372056 SCHEMBL372056 0.50 2/20
SCHEMBL2820359 SCHEMBL2820359 0.49 2/20
SCHEMBL3385661 SCHEMBL3385661 0.49 2/20
SCHEMBL2814867 SCHEMBL2814867 0.48 2/20
SCHEMBL2815105 SCHEMBL2815105 0.48 2/20
SCHEMBL2816172 SCHEMBL2816172 0.48 2/20
SCHEMBL2816322 SCHEMBL2816322 0.48 2/20
SCHEMBL2817052 SCHEMBL2817052 0.48 2/20
SCHEMBL2817829 SCHEMBL2817829 0.48 2/20
SCHEMBL2816936 SCHEMBL2816936 0.48 2/20
SCHEMBL2813901 SCHEMBL2813901 0.47 2/20
SCHEMBL2819995 SCHEMBL2819995 0.45 2/20
SCHEMBL1167921 SCHEMBL1167921 0.43 2/20
SCHEMBL120582 SCHEMBL120582 0.39 2/20
Bms-387032 Bms-387032 (SCHEMBL187401) 1.00 1/20

Clinical trials — most relevant to CDK11B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer PHASE2UNKNOWN
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation PHASE2ACTIVE_NOT_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. PHASE1/PHASE2COMPLETED
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer PHASE2RECRUITING
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations PHASE2COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors PHASE1COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) PHASE1SUSPENDED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors PHASE1COMPLETED
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK11B binder may also engage these)

ProteinNameSimilarity
CDK11A Cyclin-dependent kinase 11A 1.000 landscape →
P24788 — 0.998 P24788 →
Q7XUF4 — 0.983 Q7XUF4 →
Q80TJ7 — 0.980 Q80TJ7 →
A2XUW1 — 0.979 A2XUW1 →
Q08DZ2 — 0.978 Q08DZ2 →
Q9FGW5 — 0.977 Q9FGW5 →
Q53F19 — 0.976 Q53F19 →
Q498F0 — 0.976 Q498F0 →
Q5RHD1 — 0.976 Q5RHD1 →
Q9VPC0 — 0.976 Q9VPC0 →
Q5R814 — 0.976 Q5R814 →
Q3UQU0 — 0.975 Q3UQU0 →
U2SURP U2 snRNP-associated SURP motif-containing protein 0.975 landscape →
Q32S26 — 0.975 Q32S26 →
A2X6X1 — 0.975 A2X6X1 →
P0CH95 — 0.975 P0CH95 →
Q6K5F8 — 0.975 Q6K5F8 →
Q9HCS5 — 0.975 Q9HCS5 →
Q4LE39 — 0.974 Q4LE39 →
Q5TJG6 — 0.973 Q5TJG6 →
Q7ZTQ5 — 0.973 Q7ZTQ5 →
Q8CFC7 — 0.973 Q8CFC7 →
Q9XSC3 — 0.973 Q9XSC3 →
Q6NVE8 — 0.973 Q6NVE8 →
Q92833 — 0.972 Q92833 →
Q5HZB6 — 0.972 Q5HZB6 →
Q4KKX4 — 0.972 Q4KKX4 →
O88664 — 0.972 O88664 →
Q91YE9 — 0.972 Q91YE9 →